ESH AL 2020 | Targeting T-cell malignancies with CRISPR/Cas9 gene edited universal CAR-T
John DiPersio
• 7 Jul 2020
John DiPersio, MD, PhD, Washington University School of Medicine, Washington, WA, outlines the role of cellular therapies, particularly CRISPR/Cas9 gene-edited universal CAR T-cells, for the treatment of T-cell malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
